Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Prothena Corporation plc (PRTA) Market Cap & Valuation Ratios

Prothena Corporation plc (PRTA) has a market cap of $421.0M and a price-to-sales ratio of 7.7, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PRTAProthena Corporation plcFollow PRTA — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
421.0M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
PRTA0.4—2.4—-14.4%+427%-102%—
MNPR0.5———-2.6%——-49%
NGNE0.5——————-76%
PHAT0.5—1.9—-7.9%+110%-17%—
RGNX0.4—1.9——+12%-94%-194%
ALLO0.4—21.4————-52%
ALT0.4————+105%—-22%
AUTL0.4—1.8——+292%-211%—
SPRY0.4—3.0——+4%-185%-214%
TECX0.4———————
CCCC0.4—8.5——+2%-319%-84%
Median of these 10—2.5—-5.3%+59%-185%-76%

; EV/Sales 2.4 vs. 2.5.

Growth vs. price

each dot a company · hover or tap for values

Prothena Corporation plc — questions

What is Prothena Corporation plc's market cap?
$421.0M.
What is Prothena Corporation plc's price-to-sales ratio?
7.7.

Every figure on this page comes from Prothena Corporation plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.